ICH Meets in Estonia - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

ICH Meets in Estonia

ePT--the Electronic Newsletter of Pharmaceutical Technology

Last week, the steering committee and expert working groups (EWGs) of the International Conference on Harmonizaton (ICH) met in Tallinn, Estonia, to discuss progress on the ICH quality trio guidelines and other Step-4 documents.

The ICH Quality Implementation Working Group, which focuses on guidelines Q8 Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System, held its first training workshop during the meeting. The workshop focused on how to use design space, control strategy, and quality risk management, among other topics. Approximately 240 individuals, including inspectors, from 34 countries attended the workshop. Additional workshops will be held in Washington, DC, and in Tokyo, in October 2010.

ICH representatives also adopted Annexes 11 and 12 to the Q4B guideline titled Evaluation and Recommendation of Pharmacopoeial Text for Use in the ICH Regions to Step 4. The next phase, Step 5, requires each region to publish and implement the guideline. The annexes harmonize analytical procedures for capillary electrophoresis and sieving. Two additional Q4B annexes, Annex 13 on bulk and tapped density and Annex 14 on bacterial endotoxin, moved to Step 2, which means the six parties to ICH have reached consensus on a draft guideline.

Also of note, the Q3D EWG held its first official meeting to set limits on metal impurities in drug products and ingredients. The group has been working with pharmacopoeias around the world on this controversial industry topic. The working group is not expected to address specific tests for heavy metals.

Two new EWGs were formed to focus on genotoxic impurities and photosafety evaluation.

The next ICH meeting of the steering committee and EWGs will be held in Japan in November 2010.



blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here